An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer

Oncologist

Volumn 19, Issue 4, 2014, Pages 350-351

  Garcia Carbonero, Rocio ^a   Rivera, Fernando ^b   Maurel, Joan ^c   Ayoub, Jean Pierre M ^d   Moore, Malcolm J ^e   Cervantes, Andres ^f   Asmis, Timothy R ^g   Schwartz, Jonathan D ^h   Nasroulah, Federico ^h   Ballal, Shaila ^h   Tabernero, Josep ⁱ  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF VALENCIA   (Spain)

^g UNIVERSITY OF OTTAWA   (Canada)

^h ImClone Systems   (United States)

ⁱ VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; OXALIPLATIN; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; FOLINIC ACID; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; PROTEIN BINDING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SIZE; CARDIOPULMONARY ARREST; CLINICAL ARTICLE; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; METASTATIC COLORECTAL CANCER; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; IMMUNOLOGY; MORTALITY; NEOPLASM METASTASIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROTEIN BINDING; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84898430937     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0028     Document Type: Article

References (0)